1. Partnerships with the Jordanian Government Sector:

Jordan Food & Drug Administration (JFDA)

The IOPDDT group collaborates closely with the Jordan Food & Drug Administration (JFDA), the national regulatory authority responsible for ensuring the safety, efficacy, and quality of medicines in Jordan. Through this partnership, the group gains access to regulatory expertise, policy dialogue, and strategic guidance across the drug development and approval lifecycle. JFDA lends technical consultation on regulatory standards such as Good Manufacturing Practice (GMP) and Good Storage & Distribution Practice (GSDP), assisting our team in aligning formulation and manufacturing innovations with regulatory expectations. This collaboration is particularly important for translating our oral and parenteral drug delivery research into products that meet national regulatory requirements. It also supports joint advisory work on supply-chain security, as JFDA increasingly adopts advanced tracking programs to monitor inventory and prevent counterfeiting. By engaging with JFDA, our research group helps inform data-driven regulatory science, while benefiting from real‑world insights into post-marketing safety, pharmacovigilance, and lifecycle management of novel formulations.

2. Partnerships with the Jordanian Private Sector:

MS Pharma

Website: https://www.mspharma.com

A key industrial partner, MS Pharma, collaborates with the research group on formulation optimization and bioequivalence testing of oral and parenteral generic medicines.
Joint activities include:

Development of enhanced bioavailability oral dosage forms (e.g., solid dispersions and lipid-based systems).
Research on parenteral sustained-release injectables for local and regional markets.
Exchange of technical expertise, including access to MS Pharma’s pilot-scale manufacturing facilities and quality control laboratories.

This collaboration bridges academia and industry, ensuring the group’s innovations are industrially viable and aligned with pharmaceutical market demands in the MENA region.

3. Partnerships with the International Sector:

a. CMAC (Continuous Manufacturing & Advanced Crystallisation)

Website: https://cmac.ac.uk

The IOPDDT research group collaborates closely with CMAC (Continuous Manufacturing & Advanced Crystallisation) at the University of Strathclyde to enhance the quality, scope, and translational impact of its research in oral and parenteral drug delivery technologies. Through this partnership, CMAC provides access to state-of-the-art facilities. This technical support and provision of research resources enable the group to optimize formulation design, particle engineering, and process scalability, ensuring that innovations are industrially viable and regulatory-ready. Joint projects with CMAC include co-funded initiatives on nanoparticle-based and sustained-release injectable systems, digital process modeling, and the development of predictive formulation strategies. By combining expertise in advanced manufacturing and data-driven process analytics with the group’s focus on targeted drug delivery, this partnership fosters innovation, broadens the research agenda, and enhances the societal and academic impact of the group’s work, enabling translation of laboratory discoveries into practical and policy-relevant pharmaceutical solutions.

b. AstraZeneca (Global Pharmaceutical Company)

Website: https://www.astrazeneca.com

The group is developing strategic ties with AstraZeneca to explore opportunities in parenteral drug formulation, biologics stabilization, and drug-device combination systems.
Planned and ongoing areas of collaboration include:

Joint preformulation studies on injectable long-acting formulations and nanocarrier-based drug delivery.
Access to industrial mentorship and regulatory insights for technology transfer.
Potential Horizon Europe–funded collaborative projects focusing on novel biocompatible excipients and predictive formulation modeling.

This partnership positions the group within the global network of pharmaceutical innovation, enabling direct exposure to industry-standard formulation science and commercial translation pipelines.

Trending

Test trending

​1. Partnerships with the Jordanian Government Sector:

2. Partnerships with the Jordanian Private Sector:

1. Partnerships with the Jordanian Government Sector: